8-K: Foghorn Therapeutics Provides Financial Update for 2024 and Outlines 2025 Strategic Outlook

Foghorn Therapeutics reports a strong cash position and progress in its clinical programs, including the Phase 1 trial of FHD-909 for SMARCA4 mutated cancers.

Summary

• Foghorn Therapeutics announced its financial results for the year ended December 31, 2024, and provided a strategic outlook for 2025.
• The company's lead program, FHD-909, an oral selective SMARCA2 inhibitor, is currently in a Phase 1 trial targeting SMARCA4 mutated cancers, with non-small cell lung cancer (NSCLC) as the primary focus.
• Preclinical data for FHD-909 in combination with pembrolizumab and KRAS inhibitors will be presented at the AACR Annual Meeting in 2025.
• Foghorn is also advancing its Selective CBP degrader and Selective EP300 degrader programs towards IND, with additional preclinical data to be presented at AACR.
• The company achieved selective degradation of ARID1B and plans to provide a program update in 2025.
• As of December 31, 2024, Foghorn had $243.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027.
• Collaboration revenues for 2024 were $22.6 million, compared to $34.2 million in 2023.
• Research and development expenses were $94.5 million in 2024, down from $109.7 million in 2023.
• General and administrative expenses decreased to $28.4 million in 2024 from $32.4 million in 2023.
• The company reported a net loss of $86.6 million for 2024, compared to a net loss of $98.4 million for 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's strong cash position, progress in clinical trials, and upcoming data presentations. However, the decrease in collaboration revenue and ongoing net losses temper the overall outlook.

Positives

• The company has a strong cash position of $243.7 million, providing a cash runway into 2027.
• The Phase 1 trial of FHD-909 is enrolling well.
• The company is progressing its Selective CBP degrader and Selective EP300 degrader programs towards IND.
• Selective degradation of ARID1B has been achieved.
• The net loss decreased from $98.4 million in 2023 to $86.6 million in 2024.

Negatives

• Collaboration revenues decreased from $34.2 million in 2023 to $22.6 million in 2024, primarily due to the termination of the Merck collaboration.
• The company continues to operate at a net loss, reporting a loss of $86.6 million for 2024.

Risks

• The company's forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
• Clinical trials are subject to risks that could cause actual results to differ materially from expectations.
• The company's success depends on the successful development and commercialization of its product candidates.

Future Outlook

Foghorn Therapeutics anticipates sharing progress on its programs throughout 2025, including updates on FHD-909, Selective CBP degrader, Selective EP300 degrader, and Selective ARID1B degrader programs.

Management Comments

• In 2024, we continued our strong execution across our pipeline, which has set us up for an exciting 2025, said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
• The Phase 1 trial of FHD-909, a first-in-class oral selective SMARCA2 inhibitor for SMARCA4 mutated cancers with NSCLC as the primary target population, is enrolling well.
• Preclinical combination data of FHD-909 with pembrolizumab and novel KRAS inhibitors will be presented at AACR.
• We are continuing to progress our Selective CBP degrader and Selective EP300 degrader towards IND and will present additional preclinical data at AACR.
• Our Selective ARID1B degrader program, which addresses a synthetic lethal target implicated in up to 5% of all solid tumors, continues to make exciting advancements, and we expect to provide a program update later in 2025.
• Our balance sheet remains strong, and we look forward to sharing progress for programs throughout the year.

Industry Context

Foghorn Therapeutics is focused on developing novel medicines targeting the chromatin regulatory system, a relatively new area of drug discovery. The company's Gene Traffic Control platform aims to identify and validate drug targets within this system, potentially leading to new treatments for various cancers. The collaboration with Lilly highlights the growing interest in this field from larger pharmaceutical companies.

Comparison to Industry Standards

• Foghorn's approach to targeting the chromatin regulatory system is innovative, as traditional drug development has largely focused on other mechanisms.
• Companies like Constellation Pharmaceuticals (acquired by MorphoSys) have also been working in the field of chromatin modification, but Foghorn's Gene Traffic Control platform offers a unique approach to target identification and validation.
• The collaboration with Lilly is a positive sign, as it validates Foghorn's technology and provides access to resources and expertise.
• The $243.7 million cash position provides a runway into 2027, which is relatively strong compared to other clinical-stage biotechnology companies.

Stakeholder Impact

• Shareholders: The financial update and strategic outlook provide insights into the company's progress and future plans.
• Employees: The company's continued progress and strong cash position provide job security and opportunities for growth.
• Patients: The development of new medicines targeting the chromatin regulatory system has the potential to improve the lives of patients with cancer.
• Collaborators: The collaboration with Lilly provides access to resources and expertise, which can accelerate the development of new medicines.

Next Steps

• Present preclinical combination data of FHD-909 with pembrolizumab and KRAS inhibitors at the AACR Annual Meeting (April 25-30, 2025).
• Present preclinical data for the Selective CBP degrader program at the AACR Annual Meeting (April 25-30, 2025).
• Present preclinical data for the Selective EP300 degrader program at the AACR Annual Meeting (April 25-30, 2025).
• Provide a program update for the Selective ARID1B degrader program in 2025.
• Continue advancing the Phase 1 trial of FHD-909.

Key Dates